New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
09:17 EDTBRCM, BIIB, KING, REPYY, ISRG, DOW, TLM, WHR, MCD, JNPR, ALTR, BA, GSK, XLNX, PBYI, PEPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Intuitive Surgical (ISRG), up 12.8%... Biogen (BIIB), up 8%... Broadcom (BRCM), up 3.6%... PepsiCo (PEP), up 1.8%... Dow Chemical (DOW), up 1.5%. ALSO HIGHER: Puma Biotechnology (PBYI), up 275% after reporting positive top line results from Phase III PB272 trial, price target on stock raised to $325 from $125 at UBS, Citigroup says company a likely acquisition target after data... Talisman Energy (TLM), up 9.6% after Bloomberg reports Repsol (REPYY) may be looking to acquire. DOWN AFTER EARNINGS: Whirlpool (WHR), down 4.4%... Juniper Networks (JNPR), down 7.9%... GlaxoSmithKline (GSK), down 5.8%... Boeing (BA), down 0.8%. ALSO LOWER: Xilinx (XLNX), down 14.2% after results, downgrades at William Blair, BofA/Merrill and BMO Capital. Shares of peer Altera (ALTR) are also down 4.6%... King Digital (KING), down 2.7% after downgraded at BofA/Merrill... McDonald's (MCD), down 0.9% following downgrades at multiple firms after its earnings report yesterday.
News For PBYI;BA;MCD;XLNX;ALTR;PEP;GSK;JNPR;WHR;ISRG;BIIB;TLM;REPYY;BRCM;DOW;KING From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
March 20, 2015
06:06 EDTBIIBStocks with implied volatility above IV index mean; CTRP BIIB
Subscribe for More Information
05:37 EDTBIIBBiogen presents positive interim results from study of aducanumab
Subscribe for More Information
March 19, 2015
18:14 EDTGSKGlaxoSmithKline, Theravance announce FDA panel outcome on Breo Ellipta
GlaxoSmithKline (GSK) and Theravance (THRX) announced the outcome of the joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the United States FDA regarding the supplemental New Drug Application for Breo Ellipta as a once-daily inhaled treatment for asthma in patients aged 12 years and older. The FDA Advisory Committee voted that the efficacy and safety data for FF/VI 100/25 mcg and 200/25 mcg once daily in asthma support approval in adults 18 years of age and older (16 for, 4 against). The Committee voted that the efficacy data provides substantial evidence of a clinically meaningful benefit in adults (18 for, 2 against) and that the safety in this population has been adequately demonstrated (17 for, 3 against). The Committee voted against approval for the proposed indication in 12-17 year olds (2 for, 18 against). The Committee voted that the efficacy data was not sufficient to demonstrate the benefit (4 for, 16 against) and the safety (1 for, 19 against) has not been adequately demonstrated in this sub-population. The Committee recommended that a large LABA safety trial with FF/VI should be required in adults (13 yes, 7 no) and in 12-17 year olds (17 yes, 2 no and 1 no-vote), similar to the ongoing LABA safety trials being conducted as an FDA Post-Marketing Requirement by each of the manufacturers of LABA containing asthma treatments. FDA Advisory Committees provide non-binding recommendations for consideration by the FDA. Based on these opinions and the data presented, the FDA will make its final decision on approval, which is expected on April 30.
15:12 EDTGSKFDA panel says Breo lacks efficacy data in children with asthma, Bloomberg says
Subscribe for More Information
13:07 EDTBIIBBiogen volatility elevated into Alzheimer's data
Subscribe for More Information
07:26 EDTGSKFDA to hold a joint advisory committee meeting
The Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee discuss the supplemental New Drug Application (sNDA) 204275-S001, for fluticasone furoate and vilanterol dry powder for inhalation (with the brand name of BREO® ELLIPTA®), sponsored by Glaxo Group Limited (d/b/a GSK) for the once-daily treatment for asthma in patients aged 12 years and older in a meeting being held in Gaithersburg, Maryland on March 19 at 8 am. Webcast Link
07:12 EDTBIIBBiogen price target raised to $500 from $400 at Credit Suisse
Subscribe for More Information
07:10 EDTGSKTheravance announces trading in common stock halted as FDA meets on sNDA
Subscribe for More Information
06:33 EDTBAAir Lease leases two Boeing 777-300ERs with Air Austral
Subscribe for More Information
06:20 EDTBACytec Industries upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
March 18, 2015
14:10 EDTBABoeing, Airbus stepping pressure on supllier over seat delays, Reuters says
Subscribe for More Information
12:48 EDTBIIBFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
12:15 EDTTLM, REPYYTalisman Energy to cut 150-200 employees, WSJ reports
Talisman Energy (TLM) will cut its workforce by 150-200 employees, or about 10%-15%, in response to lower oil prices, The Wall Street Journal reports, citing a company spokesperson. In addition, Talisman, which is in the process of being acquired by Repsol (REPYY), is cutting its 2015 capital program to $2.1B, a 30% reduction from 2014 spending and lower than its prior 2015 forecast of $2.7B. The job cuts are mainly at Talisman's head office in Calgary and are not related to the Repsol takeover. Reference Link
12:01 EDTBABoeing 747-8 Intercontinental receives FAA approval for 330-minute ETOPS
Subscribe for More Information
10:31 EDTPEPPepsiCo's valuation low vs. peers, says Credit Suisse
Subscribe for More Information
09:35 EDTBAFedEx says not defering plane deliveries due to low fuel costs
Subscribe for More Information
07:56 EDTDOWDow Chemical management to meet with Deutsche Bank
Field trip to company headquarters in to be held in Midland, MI on March 18 hosted by Deutsche Bank.
07:34 EDTBIIBBiogen should report strong Alzheimer's data, says RBC Capital
Subscribe for More Information
06:38 EDTBABoeing looking to potential Malaysia deal to boost fighter jets, Reuters says
Subscribe for More Information
06:36 EDTBABoeing turns to cargo jets to overcome West coast port disruptions, WSJ says
Boeing (GE) and its suppliers -- including General Electric (GE) -- have turned to using large Ukrainian "Antonov" cargo jets to overcome supply disruptions at U.S. West coast ports, reports the Wall Street Journal, citing statements by Boeing Commercial CEO Ray Conner, who said disruptions continued even after the ports reached a deal earlier in March. "We’re still dealing with the congestion of all the things that are stuck in those ports right now," added Conner. A Boeing spokesperson said there had been "no effect" on deliveries to airlines. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use